JPS5859913A - ジアゼパム注腸液 - Google Patents
ジアゼパム注腸液Info
- Publication number
- JPS5859913A JPS5859913A JP15929081A JP15929081A JPS5859913A JP S5859913 A JPS5859913 A JP S5859913A JP 15929081 A JP15929081 A JP 15929081A JP 15929081 A JP15929081 A JP 15929081A JP S5859913 A JPS5859913 A JP S5859913A
- Authority
- JP
- Japan
- Prior art keywords
- diazepam
- enema
- polyethylene glycol
- solution
- propylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940031382 diazepam enema Drugs 0.000 title claims abstract description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 51
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229960003529 diazepam Drugs 0.000 claims abstract description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 19
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 19
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000019441 ethanol Nutrition 0.000 claims abstract description 14
- 239000005711 Benzoic acid Substances 0.000 claims abstract description 9
- 235000010233 benzoic acid Nutrition 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 9
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000019445 benzyl alcohol Nutrition 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical class OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 claims abstract description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical class O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 4
- ZYVXHFWBYUDDBM-UHFFFAOYSA-N N-methylnicotinamide Chemical compound CNC(=O)C1=CC=CN=C1 ZYVXHFWBYUDDBM-UHFFFAOYSA-N 0.000 claims abstract description 3
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 claims abstract 2
- 229940074774 glycyrrhizinate Drugs 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 6
- 239000007864 aqueous solution Substances 0.000 abstract description 5
- 238000004090 dissolution Methods 0.000 abstract description 3
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 abstract description 2
- 208000005392 Spasm Diseases 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 239000002085 irritant Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 24
- 230000007794 irritation Effects 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 241000792859 Enema Species 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 229940095399 enema Drugs 0.000 description 9
- 239000007920 enema Substances 0.000 description 9
- 239000011259 mixed solution Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 241000283977 Oryctolagus Species 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 210000000436 anus Anatomy 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- KFLRWGSAMLBHBV-UHFFFAOYSA-M sodium;pyridine-3-carboxylate Chemical compound [Na+].[O-]C(=O)C1=CC=CN=C1 KFLRWGSAMLBHBV-UHFFFAOYSA-M 0.000 description 2
- 208000002091 Febrile Seizures Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022086 Injection site pain Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038669 Respiratory arrest Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- -1 polyethylene chloride Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- ZBCAZEFVTIBZJS-UHFFFAOYSA-M sodium;2-benzamidoacetate Chemical compound [Na+].[O-]C(=O)CNC(=O)C1=CC=CC=C1 ZBCAZEFVTIBZJS-UHFFFAOYSA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15929081A JPS5859913A (ja) | 1981-10-06 | 1981-10-06 | ジアゼパム注腸液 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15929081A JPS5859913A (ja) | 1981-10-06 | 1981-10-06 | ジアゼパム注腸液 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5859913A true JPS5859913A (ja) | 1983-04-09 |
| JPS6321650B2 JPS6321650B2 (enrdf_load_stackoverflow) | 1988-05-09 |
Family
ID=15690558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP15929081A Granted JPS5859913A (ja) | 1981-10-06 | 1981-10-06 | ジアゼパム注腸液 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5859913A (enrdf_load_stackoverflow) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2887149A1 (fr) * | 2005-06-17 | 2006-12-22 | Galderma Sa | Procede de solubilisation du metronidazole |
| CN106214636A (zh) * | 2016-09-18 | 2016-12-14 | 天津金耀药业有限公司 | 一种地西泮注射液药物组合物 |
-
1981
- 1981-10-06 JP JP15929081A patent/JPS5859913A/ja active Granted
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8859603B2 (en) | 2004-06-17 | 2014-10-14 | Galderma S.A. | Method for solubilizing metronidazole |
| FR2887149A1 (fr) * | 2005-06-17 | 2006-12-22 | Galderma Sa | Procede de solubilisation du metronidazole |
| WO2006134279A3 (fr) * | 2005-06-17 | 2007-02-22 | Galderma Sa | Procede de solubilisation du metronidazole a l’aide de niacinamide et de deux glycols, solution ainsi obtenue |
| EP2204174A1 (fr) * | 2005-06-17 | 2010-07-07 | Galderma S.A. | Procédé de solubilisation du metronidazole a l'aide de niacinamide et de deux glycols, solution ainsi obtenue |
| US7981916B2 (en) | 2005-06-17 | 2011-07-19 | Galderma S.A. | Solubilizing of metronidazole |
| CN106214636A (zh) * | 2016-09-18 | 2016-12-14 | 天津金耀药业有限公司 | 一种地西泮注射液药物组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6321650B2 (enrdf_load_stackoverflow) | 1988-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3256761B2 (ja) | 症状及び疾病の治療 | |
| US4472376A (en) | Pharmaceutical insertion compositions and a process for producing the same | |
| Jacob et al. | Dimethyl sulfoxide (DMSO) toxicology, pharmacology, and clinical experience | |
| JPH0692299B2 (ja) | フロルフェニコールの薬剤組成物 | |
| WO2020221283A1 (zh) | 一种乙醇类硬化剂及其应用 | |
| JPH10158169A (ja) | 塩化トロスピウムを含んだ医薬製剤、その調整方法および使用方法 | |
| CN101123957B (zh) | 双氯芬酸及其药学上可接受盐的注射剂 | |
| JPS61212520A (ja) | 長期間の疼痛緩和をもたらす配合剤および方法 | |
| US3548052A (en) | Heparin compositions and methods of using same | |
| JPS5859913A (ja) | ジアゼパム注腸液 | |
| JP2002255852A (ja) | 口内炎用スプレー製剤 | |
| JPH04193826A (ja) | ジクロフェナクナトリウム含有の経皮吸収型消炎・鎮痛貼布剤 | |
| JPH08333265A (ja) | イブプロフェン懸濁液剤 | |
| WO2000056325A2 (de) | Ibuprofen-lösung | |
| CN116270673A (zh) | 果糖与表面活性剂共同为活性组分在制备治疗便秘药物中的应用 | |
| RU2355402C1 (ru) | Гель на основе грязи мертвого моря | |
| JPH0466847B2 (enrdf_load_stackoverflow) | ||
| JPH03284620A (ja) | 腸管洗浄用組成物 | |
| US7838034B2 (en) | Intravenous pharmaceutical form of administration | |
| McGAHAN et al. | Dissolution of gallstones using methyl tertiary-butyl ether in an animal model | |
| JPS60208911A (ja) | ジアゼパム直腸投与製剤 | |
| Fischer | Experiences in seeking an ethiodol emulsion for lymphography | |
| JPS63303931A (ja) | 経鼻投与用成長ホルモン放出活性物質製剤 | |
| RU2189238C2 (ru) | Препарат "цитросоль" для лечения эндометритов у коров | |
| CA2241502C (en) | A parenteral water-miscible non-intensely coloured injectable composition of non-steroidal anti-inflammatory drugs |